ÂÜÀòÂÒÂ×

Laurent Humeau is the Chief Scientific Officer at Inovio Pharmaceuticals. Laurent has also held the position of Senior Director, Translational Research, Human Therapeutics Division, at Intrexon Corporation. In this role, they led a multidisciplinary group for the pre-clinical development of synthetic biologics in partnership with collaborating companies, from discovery to IND submission in the following therapeutic areas: cancer immunotherapies, fibroblast-based ex-vivo gene therapy, and AAV-based gene therapies.

Duties encompassed the daily management of 3 teams with scientific, product development activities; defining CMC strategies; managing CROs; generating progress and study reports to corporate partners and President of the division; and generating scientific abstracts and publications. Laurent also implemented compliance activities through a quality program and generated related SOPs. Laurent acquired several pieces of equipment to streamline processes while boosting data output and quality.

Laurent Humeau received their Ph.D. in Blood Cell Biology from Université Paris Cité, a DEA in Blood Cell Biology from University Denis Diderot Paris 7 in France, and a Deug B and License & Matrise (B.S. & M.S,) in Cell biology, Immunology, Genetic and Embryology from University Paris VI - Pierre & Marie Curie.

They are on a team with Prakash Bhuyan - Vice President, Clinical Development, Shawn Bridy - VP Business Development, and Mark Twyman - Vice President, Commercial. Laurent Humeau reports to J. Joseph Kim, President & CEO.